ZH
RU
ES

marketing authorization

marketing authorization, Total:29 items.

In the international standard classification, marketing authorization involves: Quality, Medical sciences and health care facilities in general, Pharmaceutics, Test conditions and procedures in general.

Group Standards of the People's Republic of China, marketing authorization

• T/SHSPTA 002-2023 Specification for entrusted distribution management by drug market authorization holders

IX-EU/EC, marketing authorization

• 2014/C 337/03-2014 Summary of European Union decisions on marketing authorisations in respect of medicinal products
• 2007/C 144/06-2007 Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007
• 2008/C 188/04-2008 Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 June 2008 to 30 June 2008
• 2007/C 203/04-2007 Summary of Community decisions on marketing authorizations in respect of medicinal products - Issuing, maintenance or modification of a national marketing authorisation
• 2013/C 250/03-2013 Summary of European Union decisions on marketing authorisations in respect of medicinal products (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)
• 2012/C 107/08 CORR-2012 Corrigendum to the summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2007 to 31 December 2007 (Official Journal of the European Union C 19 of 25 January 2008)
• 2007/C 266/06-2007 Medicinal products - List of marketing authorisations granted by the EEA EFTA States for the second half of 2006 Subcommittee I - On the free movement of goods
• 2012/C 401/02-2012 Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2012 to 30 November 2012 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the
• 2013/C 154/02-2013 Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 to 30 April 2013 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)
• 2013/C 311/02-2013 Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 to 30 September 2013 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)
• 2012/C 94/01-2012 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 February 2012 to 29 February 2012 (Published pursuant to Art
• 2012/C 371/01-2012 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2012 to 31 August 2012 (Published pursuant to Article
• 2013/C 250/01-2013 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 February 2013 to 28 February 2013 (Decisions taken pursuant
• 2013/C 282/01-2013 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2013 to 31 August 2013 (Published pursuant to Article
• 2014/C 467/01-2014 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2014 to 30 November 2014 (Published pursuant to Art
• 2015/C 361/01-2015 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 September 2015 to 30 September 2015 (Published pursuant to A
• 2015/C 032/01-2015 NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 December 2014 to 31 December 2014 (Published pursuant to Art
• 2012/C 371/02-2012 Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2012 to 31 August 2012 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)
• 2013/C 154/03-2013 Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 January to 31 January 2012 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

EU/EC - European Union/Commission Legislative Documents, marketing authorization

• 2009/C 146/03-2009 Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2009 to 31 May 2009 — Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted (Published pursuant to Article 13 or Ar
• 2009/C 146/04-2009 Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2009 to 31 May 2009 — Issuing@ maintenance or modification of a national marketing authorisation (Decisions taken pursuant to Article 34 of Directive 20
• 2009/53/EC-2009 DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Directive 2001/82/EC and Directive 2001/83/EC@ as regards variations to the terms of marketing authorisations for medicinal products (Text with EEA relevance)
• 2013/C 250/02-2013 Summary of European Union decisions on marketing authorisations in respect of medicinal products (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
• 2016/C 312/03 CORR-2016 Corrigendum to Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 March 2016 to 31 March 2016 (Official Journal of the European Union C 154 of 29 April 2016)
• 2016/C 076/01-2016 NOTICES FROM EUROPEAN UNION INSTITUTIONS@ BODIES@ OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 January 2016 to 31 January 2016 (Published pursuant to Artic
• 2016/C 399/01-2016 NOTICES FROM EUROPEAN UNION INSTITUTIONS@ BODIES@ OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 September 2016 to 30 September 2016 (Published pursuant to A
• 2017/C 367/01-2017 NOTICES FROM EUROPEAN UNION INSTITUTIONS@ BODIES@ OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 September 2017 to 30 September 2017 (Published pursuant to A

RU-GOST R, marketing authorization

• GOST R 56701-2015 Medicines for medical applications. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals

Others:   license, Tellurium listed, drug launch, Listed drugs, listing, Grand listing, Domestic marketing authorization, Drug launch, Drug Marketing Authorization, Overseas listing, After listing, marketing authorization, marketing authorization, Listed drugs, Clinical listing, recently listed, Drug launch, drug launch, Listed Clinical, Drug Marketing Authorization.